| 產(chǎn)品編號 | bs-12883R-BF555 |
| 英文名稱 | Rabbit Anti-BRAF35/BF555 Conjugated antibody |
| 中文名稱 | BF555標記的乳腺癌易感基因2相關(guān)蛋白抗體 |
| 別 名 | BRAF25; BRAF35; BRCA 2 Associated Factor (35kDa); BRCA2 associated factor 35; BRCA2-associated factor 35; High Mobility Group Protein 20B; HM20B_HUMAN; HMG 20B; HMG box containing protein 20B; HMG box-containing protein 20B; HMG domain-containing protein 2; HMG domain-containing protein HMGX2; hmg20b; HMGX2; PP7706; pp8857; SMARCE1 related protein; SMARCE1-related protein; SMARCE1r; sox like; Sox like transcriptional factor; Sox-like transcriptional factor; SOXL; Structural DNA binding protein BRAF35; Structural DNA-binding protein BRAF35; SWI/SNF related; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細胞生物 轉(zhuǎn)錄調(diào)節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Mouse, (predicted: Human, Rat, Cow, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 36kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BRAF35 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation. Function: Required for correct progression through G2 phase of the cell cycle and entry into mitosis. Required for RCOR1/CoREST mediated repression of neuronal specific gene promoters. Subunit: Component of a BHC histone deacetylase complex thatcontains HDAC1, HDAC2, HMG20B/BRAF35, KDM1A, RCOR1/CoREST andPHF21A/BHC80. The BHC complex may also contain ZMYM2, ZNF217,ZMYM3, GSE1 and GTF2I. Interacts with the BRCA2 tumor suppressorprotein. Subcellular Location: Nucleus. Chromosome. Localized to condensed chromosomes in mitosis in conjunction with BRCA2. Tissue Specificity: Ubiquitously expressed in adult tissues. Similarity: Contains 1 HMG box DNA-binding domain. Database links: UniProtKB/Swiss-Prot: Q9P0W2.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
